From cleared to adopted.
Marketing for medical technology companies. Positioning that survives regulatory review and turns clinical evidence into pipeline for cautious buyers.
Clearance isn't adoption. Clinicians are skeptical, committees move slowly, and every claim has to stay inside the label. Medtech marketing often goes quiet exactly where it needs to be clearest.
Who this is for
Device, diagnostics, and digital health companies selling to clinicians and health systems. Typically post-clearance, building the commercial engine from first launch through growth stage.
Differentiation that stays inside what's cleared and still says something.
Clinical data turned into the language clinicians, health systems, and payers act on.
Search, conferences, publications: the channels that move a cautious buyer.
Pipeline by stage and source, in the format boards and investors expect.
Medical Technology We lead marketing for an FDA-cleared medical device company, from content and SEO to its CRM, reporting and lead-recycling systems.
Positioning stays inside what is cleared. We start with a commercial teardown of your positioning, claims, and visibility against the category, then write differentiation that holds up to regulatory review and still says something. Every claim we draft routes through your compliance contact before it ships, and we build that review into the weekly operating rhythm with your commercial team so it does not become the bottleneck.
Often more than one, and they read evidence differently. Clinicians are skeptical and want to see the data. Health system committees and payers each need it in their own language. We map which of those your deal actually runs through, then take the same clinical evidence and write a version each of them can act on. Committees move slowly, so the material has to survive being passed around.
The ones a skeptical clinician already pays attention to: search, conferences, and publications. A buyer evaluating your product tends to look up the evidence before taking a meeting, so we make sure the results for your category and your product answer that search with cleared claims and published data. Conferences and publications do the educating; search catches the buyer afterward. We measure each channel by evaluations started and accounts won, and we cut what does not produce either.
Pipeline by stage and by source, in the format your board and investors already expect. Every evaluation started and every account won is tagged to the channel that produced it, so the report shows which spend turned into pipeline and which did not. We review it weekly with the commercial team. When the board meets, the same numbers roll into the deck without reformatting. Impressions and traffic go in an appendix; they are not the number we answer for.
Book a 30-minute call with us. No deck, no pressure.